The role of gefitinib in the management of Asian patients with non-small cell lung cancer

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Schrump DS, Altorki NK, Henschke CL, et al. Non-small cell lung cancer. In: Ede DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. 7th edition. Philadelphia, USA: Lippincott Williams and Welkins; 2005. p. 753-810
   Google Scholar
• Catherine D, Stefan M, Estelle R, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007;17:CD004569
   Google Scholar
• Scagliotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10:4227s-4232s
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65
   PubMed Web of Science ®Google Scholar
• Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7:603-7
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
   PubMed Web of Science ®Google Scholar
• Marx J. Medicine. Why a new cancer drug works well, in some patients. Science 2004;304:658-9
   PubMedGoogle Scholar
• Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46
   PubMed Web of Science ®Google Scholar
• Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11
   PubMed Web of Science ®Google Scholar
• Sonobe M, Manabe T, Wada H, et al. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005;93:355-63
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-45
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9
   PubMed Web of Science ®Google Scholar
• Crowley J, Furusek, Kawahara M, et al. Second Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC): a model for testing population-based pharmaco-genomics [Abstract 7050]. Proc ASCO 2006;24(18S):376S
   Google Scholar
• Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14:449-54
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Purvish P, von Pawel J, et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2007;2 Suppl 4:S306
   Web of Science ®Google Scholar
• Gronberg BH, Bremnes R, Aasebo U, et al.; A Phase III Study by the Norwegian Lung Cancer Group. Pemetrexed + carboplatin vs gemcitabine + carboplatin as first line chemotherapy in stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2007;2 Suppl 4:S317
   Google Scholar
• Cho BC, Im C-K, Park M-S, et al. Phase II study of erlotinib in advanced non-small cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-33
   PubMed Web of Science ®Google Scholar
• Choong NW, Dietrich S, Seiwert T, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-7
   PubMedGoogle Scholar
• Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Gridelli C, Rossi A, Maione P, et al. Erlotinib in non-small cell lung cancer. Expert Opin Pharmacother 2007;8:2579-92
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006;51:363-8
   PubMed Web of Science ®Google Scholar
• Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week-on, 2-week-off schedule in patients with advanced solid tumors. Br J Cancer 2007;98:80-5
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Shimamura T, Monti S, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signalling. Cancer Res 2006;66:11389-98
   PubMed Web of Science ®Google Scholar
• Moasser MM, Basso Al, Averbuch SD, et al. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2 driven signalling and suppresses the growth of HER-2 overexpressing tumor cells. Cancer Res 2001;61:7184-8
   PubMed Web of Science ®Google Scholar
• Normanno N, Campiglio M, De Luca A, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65-72
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8
   PubMed Web of Science ®Google Scholar
• Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2001;20:110-24
   Web of Science ®Google Scholar
• Daneshmand M, Parolin DAE, Hirte HW, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003;9:2457-64
   PubMed Web of Science ®Google Scholar
• Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid; malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50
   PubMed Web of Science ®Google Scholar
• Herbst RS, Maddox A-M, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25
   PubMed Web of Science ®Google Scholar
• Baselga J, Rischin D, Ranson M, et al. Phase I safety pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (“Iressa” ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003;14:922-30
   PubMed Web of Science ®Google Scholar
• Shinagawa N, Yamazaki K, Asahina H, et al. Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer 2007;58:422-4
   PubMed Web of Science ®Google Scholar
• Rossi A, Maione P, Del Gaizo F, et al. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 2005;47:421-3
   PubMed Web of Science ®Google Scholar
• Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small cell lung cancer. Curr Med Res Opin 2006;22:561-73
   PubMed Web of Science ®Google Scholar
• Armour A. Gefitinib in advanced non-small cell lung cancer: clinical experience in patients of Asian origin. Asia Pacific J Clin Oncol 2007;3:66-78
   Web of Science ®Google Scholar
• Yang C-H, Shih J-Y, Chen K-C, et al. Survival outcome and predictors of gefitinib antitumor activity in east Asian chemonaive patients with advanced non-small cell lung cancer. Cancer 2006;107:1873-82
   PubMed Web of Science ®Google Scholar
• Kimura H, Kasahara K, Shibata K, et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy naїve non-small cell lung cancer. J Thorac Oncol 2006;1:260-7
   PubMed Web of Science ®Google Scholar
• Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small cell lung cancer: a Phase II study. J Clin Oncol 2006;24:64-9
   PubMed Web of Science ®Google Scholar
• Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never smokers. Clin Cancer Res 2005;11:3032-7
   PubMed Web of Science ®Google Scholar
• Reck M, Buchbolz E, Schott-von-Romer K, et al. Gefitinib monotherapy in chemotherapy-naїve patients with inoperable stage III/IV non-small cell lung cancer. Clin Lung Cancer 2006;6:406-11
   Web of Science ®Google Scholar
• Katakami N, Okazaki M, Kinose D, et al. A retrospective analysis of the outcome of patients (pts) in advanced recurrent adenocarcinoma of the lung who have received gefitinib after treatment of platinum-based regimen [Abstract]. Proc Am Soc Clin Oncol 2003;22:2679
   Google Scholar
• Goto K, Kim E, Kubota K, et al. Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer [Abstract 7098]. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 2004;22(14S)
   PubMedGoogle Scholar
• Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib (‘Iressa’;, ZD1839) on brain metastases in patients with advanced non-small cell lung cancer. Lung Cancer 2004;46:255-61
   PubMed Web of Science ®Google Scholar
• Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13:3029-43
   PubMed Web of Science ®Google Scholar
• Kaneda H, Tamura K, Kurata T, et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2004;46:247-54
   PubMed Web of Science ®Google Scholar
• Kim YH, Ishii G, Goto K, et al. Dominant papilliary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004;10:7311-7
   PubMed Web of Science ®Google Scholar
• Matsuura K, Kudoh S, Mitsuoka S, et al. Evaluating a prognostic factor in advanced adenocarcinoma of the lung treated with gefitinib [Abstract 7334]. ASCO Annual Meeting Proceedings. J Clin Oncol 2004;22(14S)
   Google Scholar
• Kishi K, Homma S, Miyamoto A, et al. Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC) [Abstract 7095]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S)
   Google Scholar
• Nakagawa M, Teramukai S, Tada H, et al. Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study [Abstract 7190]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S)
   Google Scholar
• Hotta K, Matsuo K, Ueoka H, et al. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 2005;16:1817-23
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Kiura K, Toyooka S, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced small cell lung cancer. Lung Cancer 2006;52:99-103
   PubMed Web of Science ®Google Scholar
• Mu X-L, Li L-Y, Zhang X-T, et al. Evaluation of safety and efficacy of gefitinib (‘IRESSA’, ZD1839) as monotherapy in a series of Chinese patients with advanced non-small cell lung cancer: experience from a compassionate-use programme. BMC Cancer 2004;4:51-9
   PubMed Web of Science ®Google Scholar
• Wu YL, Yang X, Yang J-J, et al. ZD1839 for the treatment of heavily pretreated non-small cell lung cancer [Abstract 7341]. ASCO Annual Proceedings. J Clin Oncol 2004;22(14S)
   Google Scholar
• Wang MZ, Li LY, Wang SL, et al. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2006;119:63-8
   PubMed Web of Science ®Google Scholar
• Zhang XT, Li LY, Chang X-Y, et al. Efficacy and correlation with predictive markers of gefitinib in pretreated Chinese patients with advanced NSCLC [Abstract 7240]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S)
   Google Scholar
• Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4383-8
   PubMed Web of Science ®Google Scholar
• Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005;11:2244-51
   PubMed Web of Science ®Google Scholar
• Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non small cell lung cancer. Int J Cancer 2005;113:109-15
   PubMed Web of Science ®Google Scholar
• Chang G-C, Chen K-C, Yang T-Y, et al. Activity of gefitinib in advanced non-small cell lung cancer with very poor performance status. Invest New Drugs 2005;23:73-7
   PubMed Web of Science ®Google Scholar
• Chiu C-H, Tsai C-M, Chen Y-M, et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005;47:129-38
   PubMed Web of Science ®Google Scholar
• Chang GC, Tsai CM, Chen KC, et al. Predictive factors of gefitinib anti-tumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol 2006;1:520-5
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-24
   PubMed Web of Science ®Google Scholar
• Sunaga N, Tomizawa Y, Yonagitani N, et al. Phase II prospective study of efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007;56:383-9
   PubMed Web of Science ®Google Scholar
• Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naїve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6
   PubMed Web of Science ®Google Scholar
• Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as the first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004
   PubMed Web of Science ®Google Scholar
• Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2007;2:22-8
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (IRESSA Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
   PubMed Web of Science ®Google Scholar
• Chang A, Parikh P, Thongprasert S, et al. Gefitinib (Iressa) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-55
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Kim E, Hirsh V, et al. Gefitinib (Iressa) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). J Thorac Oncol 2007;2 Suppl 4:S305
   Web of Science ®Google Scholar
• SeKine I, Ichinose Y, Nishiwaki Y, et al. A randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol 2007;2 Suppl 4:S339
   Google Scholar
• Forsythe B, Faul Kner K. Overview of the tolerability of gefitinib (Iressa™) monotherapy. Clinical experience in non-small cell lung cancer. Drug Saf 2004;27:1081-92
   PubMed Web of Science ®Google Scholar
• Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, anti-tumor response and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56
   PubMed Web of Science ®Google Scholar
• Zhang X, Chang A. Somatic mutations of the epidermal growth factor receptor and non-small cell lung cancer. J Med Genet 2007;44:166-72
   PubMed Web of Science ®Google Scholar
• Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44
   PubMed Web of Science ®Google Scholar
• Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinoma with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih J-Y, et al. MET amplification occurs with or without T790M mutation in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7
   PubMed Web of Science ®Google Scholar
• Sone T, Kasahara K, Kimura, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with non-small cell lung cancer. Cancer 2007;109:1836-44
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Tsuta K, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. Clin Cancer Res 2007;13:5385-90
   PubMed Web of Science ®Google Scholar
• Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumor derived DNA from pleural effusion is a practical basis for predicting response to gefitinib. Br J Cancer 2006;95:1390-5
   PubMed Web of Science ®Google Scholar
• Chin TM, Anuar D, Soo R, et al. Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 2007;53:62-70
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao Y, Wang M, et al. Detection and comparison of epidermal growth factor receptor mutations between cells and fluid of malignant pleural effusion from non-small cell lung cancer. Lung Cancer 2007; Nov 29 [Epub ahead of print]
   Google Scholar
• Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method. Clin Cancer Res 2007;13:4954-5
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol 2004;22:777-84
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:786-94
   Google Scholar
• Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska, Szcaesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007;25:1545-52
   PubMed Web of Science ®Google Scholar
• Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-92
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9
   PubMed Web of Science ®Google Scholar
• Kelly K, Chansky K, Gaspar LE, et al. Updated analysis of SWOG 0023: a randomized phase III trial of gefitinib versus placebo maintenance after definite chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer [Abstract 7513]. J Clin Oncol 2007;15:388S
   Google Scholar
• Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small-cell lung cancer. Clin Cancer Res 2007;13:2684-91
   PubMed Web of Science ®Google Scholar
• Kris MG, Riely GJ, Azzoli CG, et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial [Abstract 7575]. J Clin Oncol 2007;25:403s
   Google Scholar